undamentalytics Newsletter
Sign in

Aquestive Therapeutics, Inc. income statement

In fiscal 2025, Aquestive Therapeutics, Inc. reported revenue of $44.5m, down 22.6% on the year before, operating income of −$71.1m (a -159.5% margin) and net income of −$83.8m, or −$0.78 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue67675346514851584554
Cost of revenue——2013—1921181918
Gross profit——3233—2830402636
Research and development22232120171713201716
Selling, general and administrative25726456535332508073
Operating income−0−49−53−43−35−42−15−31−71−53
Interest expense889111076111111
Income before tax−9−61−66−56−71−54−8−44−84−78
Income tax0000000−000
Net income−9−61−66−56−71−54−8−44−84−78
Diluted EPS—−$2.96−$2.61−$1.66−$1.85−$1.12−$0.13−$0.51−$0.78−$0.65
Diluted shares (average)—21m25m34m38m49m61m87m107m120m
EBITDA4−46−50−39−32−40−14−30−71−52

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AQST vs AYTUAQST vs BFRIAQST vs DERMAQST vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aquestive Therapeutics, Inc.